AXL and MERTK are frequently overexpressed in multiple cancers including head and neck, lung, colon, lung, skin, sarcoma, and glioblastoma multiforme.212–216 McDaniel et al. identified MERTK upregulation as an inherent and adaptive feedback mechanism that leads to resistance against anti-AXL agents. The gene discussed is MERTK; the disease is cancer.